Download PDF
Thromb Haemost 2008; 99(06): 1019-1029
DOI: 10.1160/TH08-01-0006
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis

Masahito Uemura   *
1   Third Department of Internal Medicine
,
Yoshihiro Fujimura   *
2   Department of Blood Transfusion Medicine
,
Masanori Matsumoto
2   Department of Blood Transfusion Medicine
,
Hiromichi Ishizashi
2   Department of Blood Transfusion Medicine
,
Seiji Kato
2   Department of Blood Transfusion Medicine
,
Tomomi Matsuyama
1   Third Department of Internal Medicine
,
Ayami Isonishi
2   Department of Blood Transfusion Medicine
,
Masatoshi Ishikawa
1   Third Department of Internal Medicine
,
Masato Yagita
4   Kitano Hospital, Osaka, Japan
,
Chie Morioka
1   Third Department of Internal Medicine
,
Hitoshi Yoshiji
1   Third Department of Internal Medicine
,
Tatsuhiro Tsujimoto
1   Third Department of Internal Medicine
,
Norio Kurumatani
3   Department of Community Health and Epidemiology, Nara Medical University, Kashihara, Nara, Japan
,
Hiroshi Fukui
1   Third Department of Internal Medicine
› Author AffiliationsFinancial support: This work was supported in part by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (MU, YF) and from the Ministry of Health and Welfare of Japan for Blood Coagulation Abnormalities (YF).
Further Information

Publication History

Received 05 January 2008

Accepted after minor revision 13 April 2008

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

Summary

Decreased plasma ADAMTS13 activity (ADAMTS13:AC) results in the accumulation of unusually large von Willebrand factor multimer (UL-VWFM) and the formation of platelet thrombi. It remains controversial whether or not plasma ADAMTS13:AC decreases in patients with liver cirrhosis (LC), and its relationship to clinical features has not been fully investigated. We measured ADAMTS13:AC and its related parameters in plasma in 33 patients with chronic hepatitis (CH) and in 109 patients with LC. ADAMTS13:AC decreased with increasing severity of liver disease (controls means 100%, CH 87%, Child A-LC 79%, Child B-LC 63%, and Child C-LC 31%), and showed severe deficiency (<3% of controls) in five end-stage LC. Activities measured by act-ELISA strongly correlated with those determined by the VWFM assay and ADAMTS13 antigen. Multivariate analysis showed Child-Pugh score and spleen volume independent factors contributing to ADAMTS13:AC. VWFM patterns were normal in 53% of cases, degraded in 31%, and unusually large in 16%. Patients with unusually large VWFM had the lowest ADAMTS13:AC as well as the highest Child-Pugh score, serum creatinine and blood ammonia levels. Plasma inhibitor against ADAMTS13 detected in 83% of patients with severe to moderate ADAMTS13:AC deficiency mostly showed marginal zone between 0.5 and 1.0 BU/ml. The IgG-type autoantibodies specific to plasma derived-ADAMTS13 was detected by Western blot in only five end-stage LC with severe ADAMTS13:AC deficiency. In conclusion, both plasma ADAMTS13 activity and antigen levels decreased with increasing severity of cirrhosis. An imbalance between the decreased ADAMTS13:AC and its increased substrate may reflect the predisposing state for platelet thrombi formation in patients with advanced LC.

Keywords

ADAMTSI3 activity - liver cirrhosis - von Willebrand factor - thrombocytopenia - inhibitor

* These authors contributed equally to this study.


 

  • References

  • 1 Levy GG. et al. Mutations in a member of the ADAMTS13 gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
    CrossrefPubMedGoogle Scholar
  • 2 Zheng X. et al. Structure of von Willebrand factorcleaving protease (ADAMTS 13), metalloproteinase involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41089-41163.
    PubMedGoogle Scholar
  • 3 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-599.
    CrossrefPubMedGoogle Scholar
  • 4 Kokame K. et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 11902-11907.
    CrossrefPubMedGoogle Scholar
  • 5 Furlan M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
    CrossrefPubMedGoogle Scholar
  • 6 Tsai H-M. et al. Antibody to von Willebrand factorcleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
    CrossrefPubMedGoogle Scholar
  • 7 Moschowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Sac 1924; 24: 21-24.
    PubMedGoogle Scholar
  • 8 Uemura M. et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
    CrossrefPubMedGoogle Scholar
  • 9 Ferro D. et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23: 1377-1383.
    CrossrefPubMedGoogle Scholar
  • 10 Albornoz L. et al. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 1999; 30: 451-455.
    CrossrefPubMedGoogle Scholar
  • 11 Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest 1966; 45: 645-657.
    CrossrefPubMedGoogle Scholar
  • 12 Peck-Radosavljevic M. et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95: 795-801.
    PubMedGoogle Scholar
  • 13 Schoffski P. et al. Thrombopoietin serum levels are elevated in patients hepatitis B/C infection compared to other causes of chronic liver diseases. Liver 2002; 22: 114-120.
    CrossrefPubMedGoogle Scholar
  • 14 Amitrano L. et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-741.
    CrossrefPubMedGoogle Scholar
  • 15 Wanless IR. et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-1247.
    PubMedGoogle Scholar
  • 16 Oka K. et al. Intravascular coagulation in autopsy cases with liver diseases. Thromb Haemost 1979; 42: 564-570.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Mannucci PM. et al. Changes in health and disease of the metalloproteinase that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735.
    CrossrefPubMedGoogle Scholar
  • 18 Park YD. et al. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant 2002; 29: 789-794.
    CrossrefPubMedGoogle Scholar
  • 19 Uemura M. et al. Decreased Activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2005; 29: 264S-271S.
    CrossrefPubMedGoogle Scholar
  • 20 Ko S. et al. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl 2006; 12: 859-869.
    CrossrefPubMedGoogle Scholar
  • 21 Yagita M. et al. Development of ADAMTS-13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol 2005; 42: 420-421.
    PubMedGoogle Scholar
  • 22 Lisman T. et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
    CrossrefPubMedGoogle Scholar
  • 23 Feys HB. et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534-540.
    CrossrefPubMedGoogle Scholar
  • 24 Furlan M. et al. Deficiency activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103.
    PubMedGoogle Scholar
  • 25 Studt JD. et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 542-544.
    CrossrefPubMedGoogle Scholar
  • 26 Kokame K. et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
    CrossrefPubMedGoogle Scholar
  • 27 Eckmann CM. et al. Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETSVWF73 assay. J Thromb Haemost 2007; 5: 1330-1331.
    CrossrefPubMedGoogle Scholar
  • 28 Kato S. et al. Novel monoclonal antibody-based enzyme immunoassay for determinig plasma levels of ADAMTS13 activity. Transfusion 2006; 46: 1444-1452.
    CrossrefPubMedGoogle Scholar
  • 29 Pugh RNH. et al. Transection of the oesophagus for bleeding oesphageal varices. Br J Surg 1973; 60: 646-649.
    CrossrefPubMedGoogle Scholar
  • 30 Henderson JM. et al. Measurement of liver and spleen volume by computed tomography. Radiology 1981; 141: 525-527.
    CrossrefPubMedGoogle Scholar
  • 31 Arroyo V. et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International ascites club. Hepatology 1996; 23: 164-176.
    CrossrefPubMedGoogle Scholar
  • 32 Kudo M. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-1405.
    CrossrefPubMedGoogle Scholar
  • 33 Mori Y. et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002; 42: 572-580.
    CrossrefPubMedGoogle Scholar
  • 34 Yagi H. et al. Plasma Levels of ADAMTS13 antigen determined with an enzyme immunoassay using a neutralizing monoclonal antibody parallel ADAMTS13 activity levels. Int J Hematol 2007; 85: 403-407.
    CrossrefPubMedGoogle Scholar
  • 35 Ishizashi H. et al. Quantitative Western blot analysis of plasma ADAMTS13 antigen in patients with Upshaw-Schulman syndrome. Thromb Res 2007; 120: 381-386.
    CrossrefPubMedGoogle Scholar
  • 36 Macfarlane DE. et al. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-308.
    PubMedGoogle Scholar
  • 37 Warren CM. et al. Vertical agarose gel electrophoresis and electroblotting of high-molecular-weight proteins. Electrophoresis 2003; 24: 1695-1702.
    CrossrefPubMedGoogle Scholar
  • 38 Kasper CK. et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872.
    PubMedGoogle Scholar
  • 39 Hiura H. et al. Immuno-purification of plasma ADAMTS13 and its physico-chemical characterization. International Society on Thrombosis and Haemostasis Congress. Geneva: 2007: P-M-295.
    Google Scholar
  • 40 Liu F. et al. Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus. Thromb Haemost 2006; 95: 749-750.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Rieger M. et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost 2006; 95: 212-220.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Oleksowicz L. et al. Deficiency of von Willebrand’s factor-cleaving protease in patients with disseminated malignancies. Cancer Res 1999; 59: 2244-2250.
    PubMedGoogle Scholar
  • 43 Schorer AE. et al. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Brit J Haematol 1987; 67: 193-197.
    CrossrefPubMedGoogle Scholar
  • 44 Tornai I. et al. Endothelium releases more von Willebrand factor and tissue-type plasmionogen activator upon venous occlusion in patients with liver cirrhosis than in normals. Haemostasis 1993; 23: 58-64.
    PubMedGoogle Scholar
  • 45 Matsumoto M. et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004; 41: 68-74.
    CrossrefPubMedGoogle Scholar
  • 46 Ikeda K. et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
    CrossrefPubMedGoogle Scholar
  • 47 Kume Y. et al. Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats. FEBS Letters 2007; 581: 1631-1634.
    CrossrefPubMedGoogle Scholar
  • 48 Luken BM. et al. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005; 93: 267-274.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Tsai HM. et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 95: 886-892.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Lenzi M. et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut. 1999; 45: 328-329.
    CrossrefPubMedGoogle Scholar
  • 51 Hsieh MY. et al. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol 2008; 61: 333-337.
    PubMedGoogle Scholar
  • 52 Clifford BD. et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613-619.
    PubMedGoogle Scholar
  • 53 Bernardo A. et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100-106.
    CrossrefPubMedGoogle Scholar
  • 54 Reiter RA. et al. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005; 93: 554-558.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Ono T. et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-534.
    CrossrefPubMedGoogle Scholar